The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a "dummy drug" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-16.
Status change: Not Yet Recruiting → Recruiting2025-11-29